Lucid Diagnostics (LUCD) Share-based Compensation Growth (3y) (2023 - 2026)

Lucid Diagnostics (LUCD) Share-based Compensation Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. Growth (3y) (Qtr)
1 Abbott Laboratories 154.42 Bn 147.76 Bn 6.27 Bn 4.10%
2 Stryker 118.12 Bn 115.25 Bn 3.81 Bn 5.54%
3 Medtronic 101.72 Bn 93.55 Bn 5.76 Bn 5.09%
4 Boston Scientific 67.19 Bn 65.98 Bn 3.61 Bn 14.70%
5 Edwards Lifesciences 50.69 Bn 47.02 Bn 1.29 Bn 5.29%
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.09 Bn 26.97 Bn 750.30 Mn 7.15%
8 GE HealthCare Technologies 28.08 Bn 26.02 Bn 1.98 Bn 13.40%
9 Steris 19.80 Bn 19.37 Bn 697.10 Mn 12.36%
10 Lucid Diagnostics 149.20 Mn 121.33 Mn -325,000.00 -20.58%

Historic Data

Download Data
DateValue
Mar 31, 2026 -20.58%
Dec 31, 2025 -28.71%
Sep 30, 2025 -31.42%
Jun 30, 2025 -33.25%
Mar 31, 2025 -35.48%
Dec 31, 2024 -30.20%
Sep 30, 2024 -23.77%
Jun 30, 2024 -22.50%
Mar 31, 2024 5.04%
Dec 31, 2023 -100.82%
Sep 30, 2023 324.52%